25. Management of Chemotherapy Toxicities Flashcards

1
Q

this type of nausea/vomiting occurs despite prophylactic treatment and/or requires rescue

A

breakthrough nausea/vomiting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

this type of nausea/vomiting occurs during subsequent cycles when antiemetic prophylaxis and/or rescue have failed in earlier cycles

A

refractory nausea/vomiting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

explain the pathophysiology of acute CINV

A

in acute CINV, free radicals from toxic chemo stimulate the enterochromaffin cells in the GI tract, causing the release of serotonin. serotonin then binds to intestinal vagal afferent nerves via 5-HT3 receptors which trigger the chemoreceptor trigger zone in the CNS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

explain the pathophysiology of delayed CINV

A

substance P is the primary transmitter involved in delayed CINV. chemo drugs trigger the release of substance P from neurons in the central and peripheral nervous systems, which then binds to NKI receptors to induce vomiting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

this type of CINV is very amendable to drug therapy. the primary mediator is serotonin and occurs within 24 hours of chemotherapy

A

acute

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

this type of CINV has a variable response to drug therapy. the mechanism is not fully understood and occurs after 24 hours to up to one week after chemotherapy

A

delayed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

this type of CINV occurs before patients receive their chemotherapy, after a prior negative experience with chemotherapy (nausea > vomiting)

A

anticipatory

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what are some treatment-specific risk factors for N/V

A
  • emetogenicity of chemo agent
  • tumor burden
  • combo of chemo agents
  • combined modality therapy
  • rapid infusion rate
  • repetitive daily doses
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what are some patient-specific risk factors for N/V

A
  • children > adults
  • women > adults
  • alcohol history
  • hx of morning sickness
  • hx of motion sickness
  • prior CINV
  • depression and anxiety
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what are some clinical consequences of CINV

A
  • metabolic derangements
  • nutritional depletion and anorexia
  • deterioration of patients physical and mental status
  • degeneration of self-care and functional ability
  • d/c therapy***
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

these agents can be given as a single dose prior to chemo.
- be careful with Qt prolongation

A

5HT3 antagonists (e.g. Ondansetron)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

this newer agent has a strong binding affinity for 5HT3 with a long plasma half-life of 40 hours therefore effective in both acute and delayed CINV

A

Palonosetron

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what agent should always be given with a 5-HT3 antagonist before chemotherapy

A

dexamethasone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

true or false: if a patient is getting Palonosetron instead of another 5HT3 antagonist, their dose of dexamethasone would need to be increased

A

false - Palonosetron is dexamethasone sparing therefore can cut back on doses of dexamethasone with this agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

list the NK1 receptor antagonsits

A
  • Aprepitant
  • Fosaprepitant
  • Netupitant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what CYP enzymes to Aprepitant/Fosaprepitant/Netupitant induce or inhibit

A
  • moderate inhibitor of CYP3A4 (therefore if administered with dexamethasone, decrease dex dose by 50%)
  • weak inducer of CYP2C9 (can affect warfarin)
17
Q

this is a second generation AP that blocks 5HT2 receptors and D2 receptors and may be partially useful for the prevention of acute and delayed CINV (preferred for breakthrough CINV?)

A

olanzapine

18
Q

if a patient is on an HEC chemo drug, what agents should be given pre-chemo for nausea?

A
  1. dexamethasone 8-12 mg PO
  2. NK1
  3. 5HT3 antagonist
19
Q

if a patient is on a HEC chemo drug, what agents should be given post-chemo for nausea?

A
  1. dexamethasone 4 mg PO the evening of chemo then BID for 2-4 days
  2. +/- prochlorperazine or metoclopramide as needed
20
Q

if a patient is on an MEC chemo drug, what agents should be given pre-chemo for nausea?

A
  1. dexamethasone 8-12 mg PO
  2. 5HT3 antagonist
21
Q

if a patient is on an MEC chemo drug, what agents should be given post-chemo for nausea?

A
  1. dexamethasone 4 mg PO the evening of chemo then BID for 2-3 days
  2. +/- prochlorperazine or metoclopramide as needed
22
Q

if a patient is on a low emetogenicity chemo drug, what agents should be given for nausea?

A

maybe something pre-chemo and maybe something post-chemo